8-KLeadership ChangesRegulation FDExhibits & Filings

INTUITIVE SURGICAL INC 8-K Report, Executive Changes (Jul 27, 2015)

Filed July 27, 2015For Securities:ISRG

Summary

Intuitive Surgical, Inc. (ISRG) announced a significant addition to its Board of Directors with the appointment of Michael A. Friedman, M.D., effective July 23, 2015. Dr. Friedman brings a wealth of experience from leadership roles in healthcare institutions, including his tenure as Emeritus Cancer Center Director and former CEO of City of Hope, as well as prior executive positions at Pharmacia Corporation and Searle. His background also includes substantial experience with regulatory bodies, having served with the Food and Drug Administration (FDA). This appointment, which concurrently places him on the Governance and Nominating Committee, broadens the Board's expertise and oversight capabilities. The company also increased the authorized number of directors to nine to accommodate the new appointment. Dr. Friedman's compensation will include an annual cash retainer and stock-based awards, aligning his interests with those of shareholders. This move is intended to leverage his extensive medical, research, and regulatory insights to further support Intuitive Surgical's strategic objectives and governance framework.

Key Highlights

  • 1Michael A. Friedman, M.D., appointed to the Board of Directors on July 23, 2015.
  • 2Dr. Friedman joins the Governance and Nominating Committee of the Board.
  • 3The authorized number of directors on the Board was increased to nine.
  • 4Dr. Friedman possesses extensive experience from leadership roles at City of Hope, Pharmacia Corporation, Searle, and the FDA.
  • 5Compensation for Dr. Friedman includes a $50,000 annual cash retainer and an additional $4,000 for committee service.
  • 6Dr. Friedman received stock options (1,575 shares) and restricted stock units (975) as part of his appointment compensation.
  • 7A press release announcing the appointment was issued on July 27, 2015.

Frequently Asked Questions

Dr. Friedman's appointment is significant because he brings a diverse and highly relevant background to Intuitive Surgical's Board. His experience as a former CEO of a major cancer research and treatment institution (City of Hope), his executive roles in the pharmaceutical industry, and his prior service with the FDA provide valuable insights into the medical, research, and regulatory landscapes pertinent to Intuitive Surgical's operations and growth strategies.

Dr. Friedman will receive an annual cash retainer of $50,000 for his director service, plus an additional $4,000 for his membership on the Governance and Nominating Committee. He also received initial equity grants, including an option to purchase 1,575 shares of common stock and 975 restricted stock units, both subject to vesting based on continued service.

The company increased the authorized number of directors from eight to nine to accommodate the appointment of Dr. Michael A. Friedman, M.D., allowing for the expansion of the Board's collective expertise and oversight capacity.

Dr. Friedman is an Emeritus Cancer Center Director of City of Hope and previously served as its President and CEO. He also held senior positions at Pharmacia Corporation and Searle. Importantly, he has prior experience with the Food and Drug Administration (FDA), serving as Deputy Commissioner for Operations and Acting Commissioner. He also has experience as a director on other public company boards like Celgene Corporation, MannKind Corporation, and Smith & Nephew plc.